Deep decreases from high baseline tau levels were associated with the best clinical response in patients who responded to Aduhelm during clinical trials, according to new data presented at the Alzheimer’s Disease/Parkinson’s Disease 2022 international conference last week in Barcelona, Spain.
Source: Drug Industry Daily